Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.
Morten Hasselstrøm JensenOle HejlesenPeter VestergaardPublished in: Diabetes/metabolism research and reviews (2019)
These results indicate that insulin degludec has a safer profile with respect to all-cause mortality as compared with insulin glargine U100.